BMC Cancer

1. CHEN WW, Hao YX, Hong WQ, Yuan QY, et al
   Integrin-binding sialoprotein as an extracellular matrix-associated independent prognostic biomarker in glioma.
   BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16159.
   

   >> Share

   
   
2. LIU Y, Deng H, Song P, Qiu Q, et al
   Decoding lactylation heterogeneity in glioblastoma: machine learning identifies G6PC3 as a prognostic target.
   BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16225.
   

   >> Share

   
   
3. GIANNARIS E, Sedor G, Spina CS, Hsieh K, et al
   Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort study.
   BMC Cancer. 2026 May 28. doi: 10.1186/s12885-026-16242.
   

   >> Share

   
   

   
   Br J Cancer

4. KASHANI E, Sadowski MC, Phour J, Hashemi Gheinani A, et al
   Targeting the miR-19b/PPP2R5E axis enhances temozolomide response in glioblastoma via ROS-induced DNA damage.
   Br J Cancer. 2026 May 27. doi: 10.1038/s41416-026-03474.
   

   >> Share

   
   

   
   Br J Neurosurg

5. BRYANT JP, Patel N, Chesney K, Stabingas K, et al
   Insertion of a ventriculo-biliary shunt in a 3-year-old complicated by subdural biliary hygromas: a case report and review of the literature.
   Br J Neurosurg. 2026;40:517-523.
   

   >> Share

   
   
6. GUMUSBURUN E, Sayiner ZA, Eronat O, Akyilmaz DA, et al
   Clinical and biological determinants of short and long term responses to somatostatin analogue therapy in acromegaly patients.
   Br J Neurosurg. 2026;40:405-410.
   

   >> Share

   
   

   
   Childs Nerv Syst

7. MUELLER T, Piechowiak EI, Wermelinger J, Ricchizzi S, et al
   End-of-surgery MRI following pediatric neuro-oncological tumor resection.
   Childs Nerv Syst. 2026;42:232.
   

   >> Share

   
   
8. SOARES LFR, Fialho FMD, de Almeida Kuyven NG, Kurtz P, et al
   Pediatric neurocritical care and neuro-oncology in Brazil: ten-year experience at a reference unit.
   Childs Nerv Syst. 2026;42:229.
   

   >> Share

   
   

   
   Clin Cancer Res

9. LUKAS RV, Zhai L, Lauing KL, Kim M, et al
   Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.
   Clin Cancer Res. 2026 May 26. doi: 10.1158/1078-0432.CCR-26-1124.
   

   >> Share

   
   

   
   Eur J Cancer

10. MORFOUACE M, Bielle F, Razis E, McCabe MG, et al
    Response to letter re: Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
    Eur J Cancer. 2026;242:116832.
    

    >> Share

    
    
11. HASHII Y, Fujisaki H, Terashima K, Goto H, et al
    Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.
    Eur J Cancer. 2026;242:116808.
    

    >> Share

    
    
12. GUO H, Zhou J
    Letter Re "Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations".
    Eur J Cancer. 2026;242:116793.
    

    >> Share

    
    

    
    Int J Cancer

13. VANDESTEEG GN, Russum AR, Sandbulte MR, Rogan EG, et al
    Environmental Pesticide Exposure in the Etiology of Pediatric Brain Tumors and Leukemia: A Scoping Review of Epidemiological Studies.
    Int J Cancer. 2026 May 26. doi: 10.1002/ijc.70546.
    

    >> Share

    
    

    
    J Clin Oncol

14. RUDRA GUPTA T, Polley MC, Redd R, Lee EQ, et al
    Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
    J Clin Oncol. 2026 May 22:JCO2501586. doi: 10.1200/JCO-25-01586.
    

    >> Share

    
    
15. KOTECHA R, Polley MY, Vogelbaum MA, Perry A, et al
    Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma.
    J Clin Oncol. 2026 May 27:JCO2501441. doi: 10.1200/JCO-25-01441.
    

    >> Share

    
    

    
    J Neurooncol

16. JUNG IH, Yoo J, Choi S, Roh TH, et al
    Survival analysis of adult midline-located gliomas and diffuse midline gliomas: beyond the H3K27 mutation paradigm.
    J Neurooncol. 2026;178:17.
    

    >> Share

    
    
17. HWANG S, Kim PH, Kim H, Kim D, et al
    Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1.
    J Neurooncol. 2026;178:18.
    

    >> Share

    
    
18. GLYNN SE, D'Agostino R Jr, Lanier CM, R Choi A, et al
    Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients.
    J Neurooncol. 2026;178:20.
    

    >> Share

    
    
19. IZHAR M, Hori YS, Lam FC, Kalra N, et al
    Clinical utility of liquid biopsy in distinguishing true progression from radiation necrosis and pseudoprogression in malignant brain tumor.
    J Neurooncol. 2026;178:21.
    

    >> Share

    
    
20. MAI YY, Liu ZM, Zhou H, Jiang K, et al
    Role of tumor momentum in neurocognitive deficits among pediatric brainstem glioma prior to treatment: a pilot study.
    J Neurooncol. 2026;178:23.
    

    >> Share

    
    
21. TZENG CC, Chung MW, Huang YC, Chen KT, et al
    Peripheral hematological landscapes as biomarkers for detecting postoperative progression in glioblastoma multiforme: a multivariable risk scoring approach.
    J Neurooncol. 2026;178:24.
    

    >> Share

    
    
22. MALGULWAR PB, Nambirajan A, Pathak P, Faruq M, et al
    Retraction Note: Study of beta-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    J Neurooncol. 2026;178:22.
    

    >> Share

    
    
23. ZHANG J, Zhang J, Qiu W, Zhang J, et al
    Retraction Note: MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma.
    J Neurooncol. 2026;178:27.
    

    >> Share

    
    
24. TUOHY K, Badani A, Franklin A, Zacharia B, et al
    Predicting late radiation-associated neurocognitive and endocrine toxicity in patients with brain tumors.
    J Neurooncol. 2026;178:26.
    

    >> Share

    
    
25. BREHMER S, Sarria GR, Wurfel S, Sulejmani A, et al
    Intraoperative radiotherapy after resection of newly diagnosed brain metastases in adult patients - results of a prospective phase II trial (INTRAMET).
    J Neurooncol. 2026;178:28.
    

    >> Share

    
    
26. HICKMAN-CHOW DA, Luckett PH, Olufawo M, Dierker D, et al
    Predicting progression-free survival in glioblastoma with neuroimaging and machine learning.
    J Neurooncol. 2026;178:29.
    

    >> Share

    
    
27. LEON S, Maity A, Gluski J, Brown EDL, et al
    Intramedullary or invasive characteristics of spinal melanocytomas: a PRISMA compliant systematic review and pooled case analysis.
    J Neurooncol. 2026;178:30.
    

    >> Share

    
    
28. ZHOU W, Yu M, Cheng S, Zhu H, et al
    Pituitary adenomas associated with hydrocephalus: clinical characteristics, risk stratification, and clinical management.
    J Neurooncol. 2026;178:31.
    

    >> Share

    
    
29. PICHARDO-ROJAS PS, Garcia-Torrico F, Andrade-Arbaiza EA, Calderon Magdaleno LF, et al
    Radiotherapeutic management of metastatic brain disease: a two-decade meta-analysis of tumor control and neurocognitive outcomes with SRS alone versus SRS plus WBRT.
    J Neurooncol. 2026;178:32.
    

    >> Share

    
    
30. GARCIA-HIDALGO C, Garcia Kempf AM, Galdo Galian D, Consentino Hernandez JA, et al
    Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort.
    J Neurooncol. 2026;178:33.
    

    >> Share

    
    

    
    J Neurosurg

31. ZHANG M, Xiao X, Jia H, Liu Y, et al
    Assessment system for short-term lower cranial nerve dysfunction following medulla oblongata glioma surgery: risk stratification and optimal surgical strategy.
    J Neurosurg. 2026 May 29:1-12. doi: 10.3171/2025.12.JNS251593.
    

    >> Share

    
    

    
    Neuro Oncol

32. OKADA M, Subramaniam B, Geng B, Jung J, et al
    Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy.
    Neuro Oncol. 2026 May 24:noag119. doi: 10.1093.
    

    >> Share

    
    
33. PITARCH-ABAIGAR C, Pease M
    Beyond the contrast-enhancing margin: AI-guided targeting of glioblastoma infiltration.
    Neuro Oncol. 2026 May 26:noag121. doi: 10.1093.
    

    >> Share

    
    
34. 
    Corrigendum to: RGS2 promotes brain metastasis of cisplatin-resistant non-small cell lung cancer through caspase-1/IL-1beta signaling pathway.
    Neuro Oncol. 2026 May 20:noag099. doi: 10.1093.
    

    >> Share

    
    
35. HALL MD, Abdelbaki MS
    Treatment deintensification in average-risk medulloblastoma: less is more?
    Neuro Oncol. 2026 May 22:noag118. doi: 10.1093.
    

    >> Share

    
    
36. KHASRAW M, Dun MD, Arrillaga-Romany I, Verhaak RGW, et al
    Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step?
    Neuro Oncol. 2026 May 22:noag117. doi: 10.1093.
    

    >> Share

    
    
37. KIM CC, Bayik D, Raleigh DR
    Androgens drive tumor cell-autonomous and cell-nonautonomous sex differences in brain tumors.
    Neuro Oncol. 2026 May 27:noag124. doi: 10.1093.
    

    >> Share

    
    
38. ISLIM AI, Jenkinson MD
    Molecular findings of incidental meningioma may shape clinical management.
    Neuro Oncol. 2026 May 27:noag123. doi: 10.1093.
    

    >> Share

    
    
39. VOGLIS S, Schulz D, Eling N, De Souza N, et al
    Spatially-resolved single-cell imaging of melanoma brain metastases identifies localized immune patterns predictive of immune checkpoint blockade response.
    Neuro Oncol. 2026 May 28:noag128. doi: 10.1093.
    

    >> Share

    
    

    
    Neuroradiology

40. GHAEDIAN T, Aghaei H, Rakhsha A, Ghaedian M, et al
    Diagnostic accuracy of [(99m)Tc]-Tc-HYNIC-PSMA-11 SPECT/CT in differentiating tumor recurrence from post-treatment changes in glioblastoma.
    Neuroradiology. 2026 May 28. doi: 10.1007/s00234-026-04042.
    

    >> Share

    
    

    
    Neurosurgery

41. DONO A, Pichardo-Rojas P, Hsu S, Zhu JJ, et al
    Stereotactic Radiosurgery Versus Reoperation in Small Surgically Accessible Recurrent Glioblastoma.
    Neurosurgery. 2026 May 27. doi: 10.1227/neu.0000000000004091.
    

    >> Share

    
    

    
    PLoS One

42. 
    Retraction: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-kappaB/PTEN Signaling.
    PLoS One. 2026;21:e0350255.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

43. LI Y, Chen Y, Sun M, Zhou X, et al
    Delta Histogram Analysis of Synthetic MRI for Evaluating Grade and Cellular Proliferation of Meningioma.
    Radiol Imaging Cancer. 2026;8:e250419.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share